Cambridge, MA- based Chroma Medicine announced its launch with $125 Million in seed and Series A financing. Atlas Venture and Newpath Partners seeded the company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T. Rowe Price Associates, Inc., and Wellington Management in addition to all seed investors. The financing will support continued development of the company’s epigenetic editing platform and advancement of its pipeline of targeted therapeutics.
“Epigenetic editing is the next frontier in genomic medicine with the potential to transform the treatment of genetically driven diseases. By harnessing nature’s innate mechanism to modulate gene expression, we can durably and precisely control gene expression without fundamentally changing or cutting the underlying DNA sequence,” said Dr. Stehman-Breen, CEO of Chroma. “Supported by world-class founders and investors, the Chroma team is committed to deliver on the promise of this exciting platform.”
The company builds upon breakthrough epigenetic editing technologies developed...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).